Four Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting

LEXINGTON, Mass., March 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that four abstracts on its checkpoint antibodies and cancer vaccine candidates were accepted for poster presentation. The AACR 2017 Annual Meeting will be taking place in Washington, D.C. from April 1-5, 2017.

Preclinical data on Agenus' CTLA-4 and PD-1 targeted antibodies has been accepted for presentation - which the Company considers to be the backbone of the next generation of immune-oncology combinations. Data presentations will highlight how Agenus' clinical-stage CTLA-4 antagonist (AGEN1884) effectively combines with its PD-1 antagonist (AGEN2034) and other antibodies targeting the PD-1/PD-L1 axis to promote superior T cell immune responses compared to monotherapy approaches.

Data regarding the pharmacologic properties and modes of action of the INCAGN01876 (anti-GITR) and INCAGN01949 (anti-OX40) agonist antibodies, which are in clinical development and licensed to Incyte Corporation, will also be presented. In addition, Agenus will provide an overview of its three cancer vaccine platforms and present data on preclinical experiments related to heat shock protein mediated presentation of autologous (Prophage™) and individualized tumor neo-peptides (AutoSynVax™) evoking anti-tumor immune responses as well as lasting immune memory in murine models of cancer.

Poster Details:

  • CTLA-4 and PD-1
    Poster Title: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays, and in a non-human primate pharmacodynamic (PD) model 
    Poster Number: #
    27 
    Session Date: Tuesday April 4, 2017 
    Session Time: 8:00 am12:00 pm
  • GITR
    Poster Title: INCAGN01876, a unique GITR agonist antibody that facilitates GITR oligomerization
    Poster Number: #16 
    Session Date: Tuesday April 4, 2017 
    Session Time: 8:00 AM12:00 PM EST
  • OX40 
    Poster Title: INCAGN01949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells 
    Poster Number: #19 
    Session Date: Tuesday April 4, 2017 
    Session Time: 1:00 PM5:00 PM
  • Cancer Vaccines
    Poster Title: Agenus' Next Generation Cancer Vaccine Platforms
    Poster Number: #24
    Session Date: Tuesday April 4, 2017
    Session Time: 1:00 PM5:00 PM

Agenus has licensed exclusive worldwide development and commercialization rights for INCAGN01949 and INCAGN01876 to Incyte Corporation, and is partnered with Recepta Biopharma SA for certain South American rights for AGEN1884 and AGEN2034. Abstracts and posters will become available on the Company's website at http://agenusbio.com/technology/publications/ following the poster sessions.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support pre-commercial clinical programs. Agenus is based in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company's upcoming presentations. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc. 
Michelle Linn, 781-674-4541 
michelle.linn@agenusbio.com

SOURCE Agenus Inc.


print email pdf rss